Lance Large
Family Medicine · Stayton, ORNPI 1750362554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,884 and has fallen 61.6% since, to $724 in 2023. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$936
- Lilly USA, LLC$783
- Novo Nordisk$532
- Johnson & Johnson$456
- Pfizer$364
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,14098%
- Education$1702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,264 |
| AbbVie(2 entities) | 62 | $936 |
| Lilly USA, LLC | 50 | $783 |
| Novo Nordisk | 37 | $532 |
| Johnson & Johnson | 31 | $456 |
| Pfizer | 25 | $364 |
| Sanofi-aventis U.S. LLC | 18 | $358 |
| E.r. Squibb & Sons, L.L.C. | 27 | $320 |
| Amgen(2 entities) | 14 | $292 |
| Amarin Pharma, Inc. | 12 | $197 |
| GSK | 10 | $175 |
| Novartis | 11 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $146 |
| Bayer | 6 | $141 |
| Boehringer Ingelheim | 8 | $127 |
| Daiichi Sankyo Inc. | 6 | $114 |
| Biohaven Pharmaceuticals, Inc. | 6 | $109 |
| Exact Sciences | 5 | $93 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Merck | 5 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Alfasigma USA, Inc. | 3 | $66 |
| Sanofi Pasteur Inc. | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Upsher-smith Laboratories LLC | 2 | $40 |
| Eisai Inc. | 2 | $37 |
| Organon | 2 | $37 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Medline Industries LP | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Apria Healthcare LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Irhythm Technologies, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$230
- SYMBICORT$230
- BREZTRI AEROSPHERE$121
How this compares
$7,311 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $153 |
| Atorvastatin Calcium | 13 | $126 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $109 |
| Metoprolol Tartrate | 12 | $83 |
| Lisinopril | 11 | $75 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Stayton
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
- Carl EricksonMilwaukie$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.